These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 10472332)
61. [Molecular staging of testicular cancer using polymerase chain reaction of the testicular cancer-specific genes]. Nonomura N; Imazu T; Harada Y; Nozawa M; Ono Y; Fukui T; Nishimura K; Okuyama A Hinyokika Kiyo; 1999 Aug; 45(8):593-7. PubMed ID: 10500969 [TBL] [Abstract][Full Text] [Related]
62. Cancer testis antigen expression in primary and recurrent vulvar cancer: association with prognostic factors. Bellati F; Napoletano C; Tarquini E; Palaia I; Landi R; Manci N; Spagnoli G; Rughetti A; Panici PB; Nuti M Eur J Cancer; 2007 Nov; 43(17):2621-7. PubMed ID: 17950595 [TBL] [Abstract][Full Text] [Related]
63. Tumor antigen expression in melanoma varies according to antigen and stage. Barrow C; Browning J; MacGregor D; Davis ID; Sturrock S; Jungbluth AA; Cebon J Clin Cancer Res; 2006 Feb; 12(3 Pt 1):764-71. PubMed ID: 16467087 [TBL] [Abstract][Full Text] [Related]
64. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Wölfl M; Jungbluth AA; Garrido F; Cabrera T; Meyen-Southard S; Spitz R; Ernestus K; Berthold F Cancer Immunol Immunother; 2005 Apr; 54(4):400-6. PubMed ID: 15449039 [TBL] [Abstract][Full Text] [Related]
65. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Bao L; Dunham K; Lucas K Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030 [TBL] [Abstract][Full Text] [Related]
66. MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors. Grau E; Oltra S; Martínez F; Orellana C; Cañete A; Fernández JM; Hernández-Martí M; Castel V J Cancer Res Clin Oncol; 2009 Apr; 135(4):523-31. PubMed ID: 18820946 [TBL] [Abstract][Full Text] [Related]
67. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Scarcella DL; Chow CW; Gonzales MF; Economou C; Brasseur F; Ashley DM Clin Cancer Res; 1999 Feb; 5(2):335-41. PubMed ID: 10037183 [TBL] [Abstract][Full Text] [Related]
68. mRNA detection of tumor-rejection genes BAGE, GAGE, and MAGE in peritoneal fluid from patients with ovarian carcinoma as a potential diagnostic tool. Hofmann M; Ruschenburg I Cancer; 2002 Jun; 96(3):187-93. PubMed ID: 12115308 [TBL] [Abstract][Full Text] [Related]
69. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. Bolli M; Schultz-Thater E; Zajac P; Guller U; Feder C; Sanguedolce F; Carafa V; Terracciano L; Hudolin T; Spagnoli GC; Tornillo L Int J Cancer; 2005 Jul; 115(6):960-6. PubMed ID: 15751033 [TBL] [Abstract][Full Text] [Related]
70. Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer. Grah JJ; Katalinic D; Juretic A; Santek F; Samarzija M Tumori; 2014; 100(1):60-8. PubMed ID: 24675493 [TBL] [Abstract][Full Text] [Related]
71. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Jungbluth AA; Antonescu CR; Busam KJ; Iversen K; Kolb D; Coplan K; Chen YT; Stockert E; Ladanyi M; Old LJ Int J Cancer; 2001 Oct; 94(2):252-6. PubMed ID: 11668506 [TBL] [Abstract][Full Text] [Related]
72. Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). Cho HJ; Caballero OL; Gnjatic S; Andrade VC; Colleoni GW; Vettore AL; Outtz HH; Fortunato S; Altorki N; Ferrera CA; Chua R; Jungbluth AA; Chen YT; Old LJ; Simpson AJ Cancer Immun; 2006 Dec; 6():12. PubMed ID: 17137291 [TBL] [Abstract][Full Text] [Related]
73. [Analysis of CT antigen expression and humoral immunogenicity of NY-ESO-1 protein in gastric carcinoma]. Wu XJ; Wang Y; Ji JF Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 37(3):252-6. PubMed ID: 15968313 [TBL] [Abstract][Full Text] [Related]
74. Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study. Matković B; Juretić A; Spagnoli GC; Separović V; Gamulin M; Separović R; Sarić N; Basić-Koretić M; Novosel I; Kruslin B Croat Med J; 2011 Apr; 52(2):171-7. PubMed ID: 21495200 [TBL] [Abstract][Full Text] [Related]
75. Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy? Tessari A; Pilla L; Silvia D; Duca M; Paolini B; Carcangiu ML; Mariani L; de Braud FG; Cresta S Breast; 2018 Dec; 42():68-73. PubMed ID: 30189381 [TBL] [Abstract][Full Text] [Related]
76. Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers. Park TS; Groh EM; Patel K; Kerkar SP; Lee CC; Rosenberg SA J Immunother; 2016 Jan; 39(1):1-7. PubMed ID: 26641256 [TBL] [Abstract][Full Text] [Related]
77. Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group. Myšíková D; Adkins I; Hradilová N; Palata O; Šimonek J; Pozniak J; Kolařík J; Skallová-Fialová A; Špíšek R; Lischke R J Thorac Oncol; 2017 Feb; 12(2):249-257. PubMed ID: 27793776 [TBL] [Abstract][Full Text] [Related]
78. [Targeting cancer antigen (MAGE-A4, NY-ESO -1) for immunotherapy]. Imai N; Ikeda H; Shiku H Nihon Rinsho; 2012 Dec; 70(12):2125-9. PubMed ID: 23259384 [TBL] [Abstract][Full Text] [Related]
79. [Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma]. Zhang WM; Xiao G; Zhang M; Guo AL; Dong Y; Wen JM Zhonghua Bing Li Xue Za Zhi; 2005 Apr; 34(4):202-5. PubMed ID: 16091172 [TBL] [Abstract][Full Text] [Related]
80. Expression of the TRAG-3 gene in human esophageal cancer: the frequent synchronous expression of MAGE-3 gene. Ohta M; Tanaka F; Sadanaga N; Yamaguchi H; Inoue H; Mori M Oncol Rep; 2006 Jun; 15(6):1529-32. PubMed ID: 16685391 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]